Haw Par Corporation Limited
Haw Par Corporation Limited
Your view on HAWPF
Overview
What the company does, where it operates, and who runs it.
About Haw Par Corporation Limited
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Ee Lim Wee
- Headquarters
- No. 03-03 Haw Par Technocentre, Singapore, SG
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Ee Lim Wee
- Headquarters
- No. 03-03 Haw Par Technocentre, Singapore, SG
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others.
The Healthcare segment principally manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment invests primarily in quoted securities.
In addition, the company owns and leases various investment properties that have lettable area of 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Further, the company provides family and tourist oriented leisure alternatives principally in the form of oceanariums.
Haw Par Corporation Limited leases land, building, and office space, as well as offers management support services. The company was incorporated in 1969 and is based in Singapore.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Haw Par Corporation Limited, and the rating behind it. HAWPF last traded at $14.17, 13.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Haw Par Corporation Limited. Starting points for Haw Par Corporation Limited: P/E 13.0, EPS $1.04, beta 0.22 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Haw Par Corporation Limited. Haw Par Corporation Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Haw Par Corporation Limited. Trailing twelve-month EPS for Haw Par Corporation Limited stands at $1.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Haw Par Corporation Limited. Haw Par Corporation Limited has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Haw Par Corporation Limited valued side by side against its closest peers. Haw Par Corporation Limited is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Haw Par Corporation Limited, and how their positions are changing. At a $3.14B market value, institutional positions materially move Haw Par Corporation Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Haw Par Corporation Limited executives and directors. Shares of Haw Par Corporation Limited have traded between $8.37 and $14.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Haw Par Corporation Limited. Haw Par Corporation Limited is a $3.14B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Haw Par Corporation Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Haw Par Corporation Limited. Coverage tracks Haw Par Corporation Limited within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.